87 related articles for article (PubMed ID: 3415268)
1. [Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer].
Ushiki N; Jobo T; Shimoda T; Kuramoto H; Arai M
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2701-6. PubMed ID: 3415268
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of Cepharanthin for preventing leukopenia and thrombocytopenia induced by chemotherapy in breast cancer patient--prospective randomized study].
Suzuki S; Abe R; Nihei M; Kimijima I; Tsuchiya A; Nomizu T
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1195-200. PubMed ID: 2190537
[TBL] [Abstract][Full Text] [Related]
3. [Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients].
Suzuki R; Hara M; Shindoh J; Matsumoto S; Noda Y; Gonda H; Tanaka H; Taki F; Takagi K
Gan To Kagaku Ryoho; 1992 May; 19(5):647-52. PubMed ID: 1316101
[TBL] [Abstract][Full Text] [Related]
4. [Effects of massive administration of cepharanthin on chemotherapy-induced leukopenia].
Asukai K; Kimura A; Gorai I; Uemura T; Minaguchi H
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2583-7. PubMed ID: 2774588
[TBL] [Abstract][Full Text] [Related]
5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
6. [The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer].
Tsukikawa S; Oikawa H; Satoh T; Morikubo M; Komoriyama H; Hagiwara M; Kanasugi K; Yamaguchi S
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):645-8. PubMed ID: 2108613
[TBL] [Abstract][Full Text] [Related]
7. [Effect of medroxyprogesterone acetate on side effects of CAP therapy in gynecological malignant tumors].
Yanagawa Y; Okazaki T; Okamura S; Ueki M; Sugimoto O
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2393-8. PubMed ID: 2526618
[TBL] [Abstract][Full Text] [Related]
8. [CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
Chen JT; Hirai Y; Nakayama K; Shimizu Y; Yokosuka K; Teshima H; Hamada T; Fujimoto I; Yamauchi K; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1565-70. PubMed ID: 2584809
[TBL] [Abstract][Full Text] [Related]
9. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients.
Saito R; Tsuchiya S; Ishizuka T; Fueki N; Ezawa K; Minato K; Nakano H; Takise A; Kurihara M; Fueki R
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2587-93. PubMed ID: 2559129
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide].
Tanase Y; Kawaguchi R; Haruta S; Kanayama S; Yamada Y; Kobayashi H
Gan To Kagaku Ryoho; 2006 Jul; 33(7):945-50. PubMed ID: 16835485
[TBL] [Abstract][Full Text] [Related]
12. [Effect of cepharanthin on radiotherapy induced leukopenia].
Ohta T; Morita K
Rinsho Hoshasen; 1990 Apr; 35(4):471-4. PubMed ID: 2192184
[TBL] [Abstract][Full Text] [Related]
13. [Effect of cepharanthin on peripheral leukocytopenia caused by antineoplastic agents].
Kasajima T; Yamakawa M; Maeda K; Matsuda M; Dobashi M; Imai Y
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1188-96. PubMed ID: 6408999
[TBL] [Abstract][Full Text] [Related]
14. Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer.
Yano K; Matsuoka H; Seo Y; Kounoe S; Saito T; Tomoda H
Anticancer Res; 1995; 15(6B):2883-7. PubMed ID: 8669883
[TBL] [Abstract][Full Text] [Related]
15. [A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
Chylak V; Krusić J; Kolarić K
Jugosl Ginekol Perinatol; 1988; 28(1-2):41-3. PubMed ID: 3398564
[No Abstract] [Full Text] [Related]
16. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
17. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the effectiveness and adverse effects of the drug combinations CAP and CEP in the therapy of patients in the advanced stages of ovarian cancer].
Hernádi Z; Juhász B; Póka R; Mahunka I; Lampé L
Orv Hetil; 1987 Nov; 128(47):2457-61. PubMed ID: 3320851
[No Abstract] [Full Text] [Related]
19. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
20. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.
Sieja K; Talerczyk M
Gynecol Oncol; 2004 May; 93(2):320-7. PubMed ID: 15099940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
